Combination of Metformin and Epigallocatechin-3-Gallate Lowers Cortisol, 11β-Hydroxysteroid Dehydrogenase Type 1, and Blood Glucose Levels in Sprague Dawley Rats with Obesity and Diabetes

• DOI: 10.7570/jomes23080
• Publication Date: 2024-08-05T01:15:07Z
• Authors: Diana Mazaya Atsa...; Nyoman Suci Widya...; Muflihatul Muniroh; Neni Susilaningsih; Nani Maharani
• Keywords: epigallocatechin gallate; obesity; 11-beta-hydroxysteroid dehydrogenase type 1; diabetes mellitus; blood glucose; Original Article; hydrocortisone; RC648-665; Diseases of the endocrine glands. Clinical endocrinology

Background:The combined effects of metformin and epigallocatechin-3-gallate (EGCG) on cortisol, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), blood glucose levels have not been investigated.This study evaluated the effectiveness combining EGCG with in regulating those a rat model diet-induced diabetes obesity.Methods: Thirty diabetic obese rats high-fat diet were treated daily for 28 days (100 mg/kg body weight/day), (200 or both.Control groups comprised lean rats, untreated metformin-only-treated rats.Blood samples collected to measure cortisol fasting (FBG) liver tissue examined 11β-HSD1 levels.Results: Rats receiving combination therapy had significantly reduced (from 36.70±15.13 31.25±7.10ng/mL) compared but monotherapy.Rats monotherapy lower (92.68±10.82and 93.74±18.11ng/L vs. 120.66±14.00ng/L).Combination FBG (440.83±133.3 140.50±7.36mg/dL 480.67±86.32 214.17±102.78mg/dL, respectively) by approximately 68.1% 55.4% rats. Conclusion:Combining exhibited synergistic managing diabetes, leading improved outcomes reduction baseline along levels.